Effects of the administration of cholera toxin as a mucosal adjuvant on the immune and protective response induced by Proteus mirabilis MrpA fimbrial protein in the urinary tract

Microbiology and Immunology

Volumn 53, Issue 4, 2009, Pages 233-240

  Scavone, Paola ^a   Rial, Analía ^b   Umpierrez, Ana ^a   Chabalgoity, Alejandro ^b   Zunino, Pablo ^a  

^a INSTITUTO DE INVESTIGACIONES BIOLÓGICAS CLEMENTE ESTABLE   (Uruguay)

^b DEPARTAMENTO DE BIOQUÍMICA   (Uruguay)

Author keywords

Cholera toxin; MrpA; Proteus mirabilis; Urinary tract infection

Indexed keywords

CHOLERA TOXIN; FIMBRIA PROTEIN; GAMMA INTERFERON; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; MRPA PROTEIN; PROTEIN SUBUNIT; UNCLASSIFIED DRUG; BACTERIAL PROTEIN; BACTERIAL VACCINE; BACTERIUM ANTIBODY; IMMUNOLOGICAL ADJUVANT; MRPA PROTEIN, PROTEUS MIRABILIS;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BACTERIAL COLONIZATION; BLADDER; CONTROLLED STUDY; DRUG ACTIVITY; HEMAGGLUTINATION; HUMORAL IMMUNITY; IMMUNOMODULATION; KIDNEY; MOUSE; NONHUMAN; PROTEUS MIRABILIS; URINARY TRACT; VACCINATION; ANIMAL; BACTERIAL COUNT; BLOOD; FEMALE; IMMUNOLOGY; MICROBIOLOGY; PROTEUS INFECTION; SECRETION; URINARY TRACT INFECTION; URINE;

ANIMALIA; BACTERIA (MICROORGANISMS); MUS; PROTEUS MIRABILIS;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTIBODIES, BACTERIAL; BACTERIAL PROTEINS; BACTERIAL VACCINES; CHOLERA TOXIN; COLONY COUNT, MICROBIAL; FEMALE; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; INTERFERON-GAMMA; KIDNEY; MICE; PROTEUS INFECTIONS; PROTEUS MIRABILIS; URINARY BLADDER; URINARY TRACT; URINARY TRACT INFECTIONS;

EID: 70249121054     PISSN: 03855600     EISSN: 13480421     Source Type: Journal    
DOI: 10.1111/j.1348-0421.2009.00111.x     Document Type: Article

References (35)

1. Krieger J.N. (2002) Urinary tract infections: what's new? J Urol 168: 2351-2358.
2. O'Hanley P. (1996) Prospects for urinary tract infection vaccines. In:Mobley H.L.T.,Warren J.W., eds. Urinary tract infection: molecular pathogenesis and clinical management.Washington, DC: ASM Press, pp. 405-425.
3. Warren J.W., Tenney J.H., Hoopes J.M., Muncie H.L., Anthony W.C. (1982) A prospective microbiologic study of bacteriuria in patients with chronic indwelling urethral catheters. J Infect Dis 146: 719-723.
4. Senior B.W. (1978) The special affinity of particular types of P. mirabilis for the urinary tract. J Med Microbiol 12: 1-8.
5. Stamm W.E., Martin S.M., Benett J.V. (1997) Epidemiology of nosocomial infections due to gram negative bacilli: aspects relevant to development and use of vaccines. J Infect Dis 136: 151-160.
6. Coker C., Poore C.A. Li X., Mobley H.L.T. (2000) Pathogenesis of Proteus mirabilis urinary tract infection. Microbes Infect 2: 1497-1505.
7. Rozalski A., Sidorczyk Z., Kotelko K. (1997) Potential virulence factors of Proteus bacilli. Microbiol Mol Biol Rev 61: 65-69.
8. Zunino P., Geymonat L., Allen A.G., Preston A., Sosa V., Maskell D.J. (2001) New aspects of the role of MR/P fimbriae in Proteus mirabilis urinary tract infection. FEMS Immunol Med Microbiol 31: 113-120.
9. Bahrani F. K., Mobley H. L. (1994) Proteus mirabilis MR/P fimbrial operon: genetic organization, nucleotide sequence, and conditions for expression. J Bacteriol 176: 3412-3419.
10. Soto G. E., Hultgren S.J. (1999) Bacterial adhesins: common themes and variations in architecture and assembly. J Bacteriol 181: 1059-1071.
11. Li X., Erbe J.L., Lockatell C.V., Johnson D.E., Jobling M.G., Holmes R.K., Mobley H.L. (2004) Use of translational fusion of the MrpH fimbrial adhesin-binding domain with the cholera toxin A2 domain, coexpressed with the cholera toxin B subunit, as an intranasal vaccine to prevent experimental urinary tract infection by Proteus mirabilis. Infect Immun 72: 7306-7310.
12. Pellegrino R., Galvalisi U., Scavone P., Sosa V., Zunino P. (2003) Evaluation of Proteus mirabilis structural fimbrial proteins as antigens against urinary tract infections. FEMS Immunol Med Microbiol 15: 103-110.
13. Scavone P., Sosa V., Pellegrino R., Galvalisi U., Zunino P. (2004) Mucosal vaccination of mice with recombinant Proteus mirabilis structural fimbrial proteins. Microbes Infect 6: 853-860.
14. Holmgren J., Czerkinsky C. (2005) Mucosal immunity and vaccines. Nat Med 11: S45-S53.
15. Gill D.M., Rappaport R.S. (1979) Origin of the enzymatically active A1 fragment of cholera toxin. J Infect Dis 139: 674-680.
16. Elson C.O., Ealding W. (1984) Generalized systemic and mucosal immunity in mice after mucosal stimulation with cholera toxin. J Immunol 132: 2736-2741.
17. Spangler B.D. (1992) Structure and function of cholera toxin and the related Escherichia coli heat-labile enterotoxin. Microbiol Rev 56: 622-647.
18. Scavone P., Miyoshi A., Rial A., Chabalgoity A., Langella P., Azevedo V., Zunino P. (2007) Intranasal immunisation with recombinant Lactococcus lactis displaying either anchored or secreted forms of Proteus mirabilis MrpA fimbrial protein confers specific immune response and induces a significant reduction of kidney bacterial colonization in mice. Microbes Infect 9: 821-828.
19. Zunino P., Geymonat L., Allen A.G., Legnani-Fajardo C., Maskell D.J. (2000) Virulence of a Proteus mirabilis ATF isogenic mutant is not impaired in a mouse model of ascending urinary tract infection. FEMS Immunol Med Microbiol 29: 137-143.
20. Studier F.W., Moffatt B.A. (1985) Use of a bacteriophage T7 RNA poly-merase to direct selective high-level expression of cloned genes. J Mol Biol 189: 113-130.
21. Smith P.K., Krohn R.I., Hermanson G.T., Mallia A.K., Gartner F.H., Provenzano M.D., Fujimoto E.K., Goeke N.M., Olson B.J., Klenk D.C. (1985) Measurement of protein using bicinchoninic acid. Anal Biochem 150: 76-85.
22. Zunino P., Piccini C., Legnani-Fajardo C. (1994) Flagellate and non-flagellate Proteus mirabilis in the development of experimental urinary tract infection. Microb Pathog 16: 379-385.
23. Johnson J.R., in H.L.T. Mobley, J.W.Warren (1996) Urinary Tract Infections.Washington, DC: ASM Press, pp. 95-118.
24. Mutnick A.H., Turner P.J., Jones R.N. (2002) Emerging antimicrobial resistances among Proteus mirabilis in Europe: report from the MYSTIC Program (1997-2001). Meropenem Yearly Susceptibility Test Information Collection. J Chemother 14: 253-258.
25. Johanson E.L., Wassen L., Holmgren J., Jertborn M., Rudin A. (2001) Nasal and vaginal vaccinations have differential effects on antibody responses in vaginal and cervical secretions in humans. Infect Immun 69: 7481-7486.
26. Johanson E.L., Bergquist C., Edebo A., Johansson C., Svennerholm A.M. (2004) Comparison of different routes of vaccination for eliciting antibody responses in the human stomach. Vaccine 22: 984-990.
27. Kozlowski P.A., Cu-Uvin S., Neutra M.R., Flanigan T.P. (1997) Comparison of the oral, rectal and vaginal immunisation for induction of antibodies in rectal and genital tract secretion of women. Infect Immun 65: 1387-1394.
28. Rudin A., Riise G.C., Holmgren J. (1999) Antibody responses in the lower respiratory tract and male urogenital tract in humans after nasal and oral vaccination with cholera toxin B subunit. Infect Immun 67: 2884-2890.
29. Isaka M., Zhao Y., Nobusawa E., Nakajima S., Nakajima K., Yasuda Y., Matsui H., Hasegawa T., Maeyama J., Morokuma K., Ohkuma K., Tochikubo K. (2008) Protective effect of nasal immunisation of influenza virus haemagglutinin with recombinant cholera toxin B subunit as a mucosal adjuvant in mice. Microbiol Immunol 52: 55-63.
30. Watanabe I., Hagiwara Y., Kadowaki S.E., Yoshikawa T., Komase K., Aizawa C., Kiyono H., Takeda Y., McGhee J.R., Chiba J., Sata T., Kurata T., Tamura S. (2002) Characterization of protective immune responses induced by nasal influenza vaccine containing mutant cholera toxin as a safe adjuvant (CT112K). Vaccine 20: 3443-3455.
31. Renegar K.B., Small P.A. Jr., Boykins L.G.,Wright P.F. (2004) Role of IgA versus IgG in the control of influenza viral infection in the murine respiratory tract. J Immunol 173: 1978-86.
32. Kuklin N.A., Daheshia M., Chun S., Rouse B.T. (1998) Role of mucosal immunity in herpes simplex virus infection. J Immunol 160: 5998-6003.
33. Matsuo K.Y.T., Asanuma H., Iwasaki T., Hagiwara Y., Chen Z., Kadowaki S.E., Tsujimoto H., Kurata T., Tamura S.I. (2000) Induction of innate immunity by nasal influenza vaccine administered in combination with an adjuvant (cholera toxin). Vaccine 18: 2713-2722.
34. Moschos S.A., Bramwell V.W., Somavarapu S., Alpar H.O. (2004) Adjuvant synergy: the effects of nasal coadministration of adjuvants. Immunol Cell Biol 82: 628-637.
35. Yang X., Walters N., Robison A., Trunkle T., Pascual D.W. (2007) Nasal immunisation with recombinant Brucella melitensis bp26 and trigger factor with cholera toxin reduces B. melitensis colonization. Vaccine 25: 2261-2268.